If successful, neuro-specific designs could overcome the limitations of repurposing metabolic GLP-1s and establish a new standard for neurotherapeutics The broader issue is that we lack a full understanding of GLP-1s underlying biochemical mechanisms
Coverage for GLP-1 medications (such as semaglutide and tirzepatide) and obesity treatment varies significantly across Humana plans in Arizona
To assess this, randomized trials typically evaluate the primary outcome of major adverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal stroke, and non-fatal myocardial infarction (MI)
Download Shotsy for Free 4.9 stars from 25K+ ratings on the App Store
Patients in Bluffton, South Carolina, with a body mass index of 30 or more, or a BMI of 27 or higher accompanied by conditions like hypertension, type 2 diabetes, or high cholesterol, may qualify
Individual trial results Looking at each drug independently reinforces the pattern